{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:29:03Z","timestamp":1791325743671,"version":"4.3.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10072-025-08649-y","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T02:23:42Z","timestamp":1769653422000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dose-Dependent efficacy and safety of Brexpiprazole in agitation associated with dementia in Alzheimer\u2019s disease: A systematic review and meta-analysis"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8938-0435","authenticated-orcid":false,"given":"Hammad","family":"Javaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umaima","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meeram","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamikha","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnoor","family":"Arfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryyam","family":"Aqeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erum","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Nabeel","family":"Saddique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Qadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Shamoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"8649_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.trci.2019.10.004","volume":"5","author":"M Cloutier","year":"2019","unstructured":"Cloutier M, Gauthier-Loiselle M, Gagnon\u2010Sanschagrin P, Guerin A, Hartry A, Baker RA et al (2019) Institutionalization risk and costs associated with agitation in Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions 5:851\u201361. https:\/\/doi.org\/10.1016\/j.trci.2019.10.004","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"key":"8649_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14737175.2024.2407836","volume":"25","author":"K Zhong","year":"2025","unstructured":"Zhong K, Cummings J (2025) A critical review of Brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer\u2019s disease. Expert Rev Neurother 25:5\u201313. https:\/\/doi.org\/10.1080\/14737175.2024.2407836","journal-title":"Expert Rev Neurother"},{"key":"8649_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1192\/bjpo.bp.117.005181","volume":"3","author":"G Livingston","year":"2017","unstructured":"Livingston G, Barber J, Marston L, Rapaport P, Livingston D, Cousins S et al (2017) Prevalence of and associations with agitation in residents with dementia living in care homes: MARQUE cross-sectional study. BJPsych Open 3:171\u20138. https:\/\/doi.org\/10.1192\/bjpo.bp.117.005181","journal-title":"BJPsych Open"},{"issue":"12","key":"8649_CR4","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jamaneurol.2023.3810","volume":"80","author":"D Lee","year":"2023","unstructured":"Lee D, Slomkowski M, Hefting N, Chen D, Larsen KG, Kohegyi E et al (2023) Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial. JAMA Neurol 80:1307. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3810","journal-title":"JAMA Neurol"},{"key":"8649_CR5","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1093\/gerona\/glz045","volume":"74","author":"RE Kheirbek","year":"2019","unstructured":"Kheirbek RE, Fokar A, Little JT, Balish M, Shara NM, Boustani MA et al (2019) Association between antipsychotics and all-cause mortality among community-dwelling older adults. J Gerontol A Biol Sci Med Sci 74:1916\u201321. https:\/\/doi.org\/10.1093\/gerona\/glz045","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"8649_CR6","doi-asserted-by":"publisher","DOI":"10.1176\/appi.pn.2023.07.7.17","volume":"58","author":"M Moran","year":"2023","unstructured":"Moran M (2023) FDA approves Rexulti for agitation associated with dementia due to Alzheimer\u2019s disease. Psychiatr News 58:appi.pn.2023.07.7.17. https:\/\/doi.org\/10.1176\/appi.pn.2023.07.7.17","journal-title":"Psychiatr News"},{"key":"8649_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.64719\/pb.4399","volume":"51","author":"AN Edinoff","year":"2021","unstructured":"Edinoff AN, Wu NW, Maxey BS, Ren AL, Leethy KN, Girma B et al (2021) Brexpiprazole for the treatment of schizophrenia and major depressive disorder: A comprehensive review of Pharmacological considerations in clinical practice. Psychopharmacol Bull 51:69\u201395","journal-title":"Psychopharmacol Bull"},{"key":"8649_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","volume":"28","author":"GT Grossberg","year":"2020","unstructured":"Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M et al (2020) Efficacy and safety of Brexpiprazole for the treatment of agitation in Alzheimer\u2019s dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry 28:383\u2013400. https:\/\/doi.org\/10.1016\/j.jagp.2019.09.009","journal-title":"Am J Geriatr Psychiatry"},{"key":"8649_CR9","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1002\/alz.14282","volume":"20","author":"Y Nakamura","year":"2024","unstructured":"Nakamura Y, Adachi J, Hirota N, Iba K, Shimizu K, Nakai M et al (2024) Brexpiprazole treatment for agitation in Alzheimer\u2019s dementia: a randomized study. Alzheimers Dement 20:8002\u201311. https:\/\/doi.org\/10.1002\/alz.14282","journal-title":"Alzheimers Dement"},{"key":"8649_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/alz.092333","volume":"20","author":"M Brubaker","year":"2024","unstructured":"Brubaker M, Wang D, Chumki SR, Such P, Zhang Z, Palma AM (2024) Efficacy of brexpiprazole on agitation in patients with dementia due to Alzheimer\u2019s disease exhibiting behaviors most bothersome to caregivers: post hoc pooled analysis of two randomized controlled trials. Alzheimer\u2019s & Dementia 20:e092333. https:\/\/doi.org\/10.1002\/alz.092333","journal-title":"Alzheimer's & Dementia"},{"key":"8649_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/jopsys.jopsys_27_23","volume":"3","author":"A Varadharajan","year":"2024","unstructured":"Varadharajan A, Issac TG (2024) Brexpiprazole \u2013 Banishing Behavioral and Psychological Symptoms of Dementia. J Psychiatry Spectr 3:62\u20133. https:\/\/doi.org\/10.4103\/jopsys.jopsys_27_23","journal-title":"J Psychiatry Spectr"},{"key":"8649_CR12","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions | (2025) Cochrane n.d. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook"},{"key":"8649_CR13","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"8649_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-024-02356-6","volume":"24","author":"A Abbas","year":"2024","unstructured":"Abbas A, Hefnawy MT, Negida A (2024) Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis. BMC Med Res Methodol 24:243. https:\/\/doi.org\/10.1186\/s12874-024-02356-6","journal-title":"BMC Med Res Methodol"},{"key":"8649_CR15","unstructured":"Risk of bias tools - robvis (2025) (visualization tool) n.d. https:\/\/www.riskofbias.info\/welcome\/robvis-visualization-tool"},{"key":"8649_CR16","unstructured":"Risk of bias tools - RoB 2 (2025) tool n.d. https:\/\/www.riskofbias.info\/welcome\/rob-2-0-tool"},{"key":"8649_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"8649_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2024.105173","volume":"25","author":"D Lee","year":"2024","unstructured":"Lee D, Clark ED, Antonsdottir IM, Porsteinsson AP (2024) Brexpiprazole for agitation associated with dementia due to Alzheimer\u2019s disease. J Am Med Dir Assoc 25:105173. https:\/\/doi.org\/10.1016\/j.jamda.2024.105173","journal-title":"J Am Med Dir Assoc"},{"key":"8649_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3371\/CSRP.MCCI.010316","volume":"9","author":"J McEvoy","year":"2016","unstructured":"McEvoy J, Citrome L (2016) Brexpiprazole for the treatment of schizophrenia: a review of this novel Serotonin-Dopamine activity modulator. Clin Schizophr Relat Psychoses 9:177\u2013186. https:\/\/doi.org\/10.3371\/CSRP.MCCI.010316","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"8649_CR20","doi-asserted-by":"publisher","first-page":"852","DOI":"10.4103\/indianjpsychiatry_197_25","volume":"67","author":"JVA Fernandes","year":"2025","unstructured":"Fernandes JVA, Ramos JVdeO, Vilar LADS, Holanda MMdeA (2025) Brexpiprazole for agitation in Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized controlled trials. Indian J Psychiatry 67:852\u201361. https:\/\/doi.org\/10.4103\/indianjpsychiatry_197_25","journal-title":"Indian J Psychiatry"},{"key":"8649_CR21","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jagp.2024.11.003","volume":"33","author":"VM Aga","year":"2025","unstructured":"Aga VM (2025) Brexpiprazole for the treatment of agitation in Alzheimer\u2019s disease dementia: clinical uncertainties and the path forward. Am J Geriatr Psychiatry 33:322\u2013329. https:\/\/doi.org\/10.1016\/j.jagp.2024.11.003","journal-title":"Am J Geriatr Psychiatry"},{"key":"8649_CR22","first-page":"812","volume":"54","author":"N Hirono","year":"2002","unstructured":"Hirono N, Tsukamoto N, Inoue M, Moriwaki Y, Mori E (2002) [Predictors of long-term institutionalization in patients with Alzheimer\u2019s disease: role of caregiver burden]. No To Shinkei 54:812\u20138","journal-title":"No To Shinkei"},{"key":"8649_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3233\/JAD-170518","volume":"61","author":"CM Black","year":"2017","unstructured":"Black CM, Fillit H, Xie L, Hu X, Kariburyo MF, Ambegaonkar BM et al (2017) Economic burden, mortality, and institutionalization in patients newly diagnosed with Alzheimer\u2019s disease. J Alzheimers Dis 61:185\u201393. https:\/\/doi.org\/10.3233\/JAD-170518","journal-title":"J Alzheimers Dis"},{"key":"8649_CR24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/0898264304274252","volume":"17","author":"DW Gilley","year":"2005","unstructured":"Gilley DW, McCann JJ, Bienias JL, Evans DA (2005) Caregiver psychological adjustment and institutionalization of persons with Alzheimer\u2019s disease. J Aging Health 17:172\u2013189. https:\/\/doi.org\/10.1177\/0898264304274252","journal-title":"J Aging Health"},{"key":"8649_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2217\/nmt-2020-0013","volume":"10","author":"L Stummer","year":"2020","unstructured":"Stummer L, Markovic M, Maroney M (2020) Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer\u2019s disease. Neurodegener Dis Manag 10:205\u2013217. https:\/\/doi.org\/10.2217\/nmt-2020-0013","journal-title":"Neurodegener Dis Manag"},{"key":"8649_CR26","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1001\/jamaneurol.2023.3967","volume":"80","author":"C Ballard","year":"2023","unstructured":"Ballard C (2023) Brexpiprazole for the treatment of agitation and aggression in Alzheimer disease. JAMA Neurol 80:1272. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3967","journal-title":"JAMA Neurol"},{"key":"8649_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3390\/psychiatryint4030019","volume":"4","author":"H Qasim","year":"2023","unstructured":"Qasim H, Simpson MD, Cox JL (2023) Clinical trial studies of antipsychotics during symptomatic presentations of agitation and\/or psychosis in Alzheimer\u2019s dementia: a systematic review. Psychiatry Int 4:174\u2013199. https:\/\/doi.org\/10.3390\/psychiatryint4030019","journal-title":"Psychiatry Int"},{"key":"8649_CR28","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22662.1","volume":"9","author":"F Caraci","year":"2020","unstructured":"Caraci F, Santagati M, Caruso G, Cannav\u00f2 D, Leggio GM, Salomone S et al (2020) New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer\u2019s disease: focus on brexpiprazole and pimavanserin. F1000Res 9:686. https:\/\/doi.org\/10.12688\/f1000research.22662.1","journal-title":"F1000Res"},{"key":"8649_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2024-301019","volume":"27","author":"W L\u00fc","year":"2024","unstructured":"L\u00fc W, Liu F, Zhang Y, He X, Hu Y, Xu H et al (2024) Efficacy, acceptability and tolerability of second-generation antipsychotics for behavioural and psychological symptoms of dementia: a systematic review and network meta-analysis. BMJ Ment Health 27:e301019. https:\/\/doi.org\/10.1136\/bmjment-2024-301019","journal-title":"BMJ Ment Health"},{"key":"8649_CR30","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1007\/s10072-024-07576-8","volume":"45","author":"G Marinheiro","year":"2024","unstructured":"Marinheiro G, Dantas JM, Mutarelli A, Menegaz De Almeida A, Monteiro GDA, Zerlotto DS et al (2024) <article-title update=\"added\">Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer\u2019s disease: a meta-analysis of randomized controlled trials. Neurol Sci 45:4679\u201386. https:\/\/doi.org\/10.1007\/s10072-024-07576-8","journal-title":"Neurol Sci"},{"key":"8649_CR31","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/08039488.2016.1191537","volume":"70","author":"M Kuronen","year":"2016","unstructured":"Kuronen M, Kautiainen H, Karppi P, Hartikainen S, Koponen H (2016) Antipsychotic drug use and associations with neuropsychiatric symptoms in persons with impaired cognition: a cross-sectional study. Nord J Psychiatry 70:621\u2013625. https:\/\/doi.org\/10.1080\/08039488.2016.1191537","journal-title":"Nord J Psychiatry"},{"key":"8649_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18553\/jmcp.2012.18.S5-B.1","volume":"18","author":"AR Maher","year":"2012","unstructured":"Maher AR, Theodore G (2012) Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm 18:1\u201320. https:\/\/doi.org\/10.18553\/jmcp.2012.18.S5-B.1","journal-title":"J Manag Care Pharm"},{"issue":"Suppl 10","key":"8649_CR33","first-page":"13","volume":"67","author":"SR Marder","year":"2006","unstructured":"Marder SR (2006) A review of agitation in mental illness: treatment guidelines and current therapies. J Clin Psychiatry 67(Suppl 10):13\u201321","journal-title":"J Clin Psychiatry"},{"key":"8649_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4140\/TCP.n.2025.115","volume":"40","author":"EM Hitt","year":"2025","unstructured":"Hitt EM (2025) Brexpiprazole: a balance of risks and benefits. Sr Care Pharm 40:115\u201322. https:\/\/doi.org\/10.4140\/TCP.n.2025.115","journal-title":"Sr Care Pharm"},{"key":"8649_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40263-024-01133-9","volume":"39","author":"C Imbimbo","year":"2025","unstructured":"Imbimbo C, Cotta Ramusino M, Leone S, Mazzacane F, De Franco V, Gatti A et al (2025) Emerging pharmacological approaches for psychosis and agitation in Alzheimer\u2019s disease. CNS Drugs 39:143\u201360. https:\/\/doi.org\/10.1007\/s40263-024-01133-9","journal-title":"CNS Drugs"},{"key":"8649_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s40473-019-00181-6","volume":"6","author":"MT Thiyagarajah","year":"2019","unstructured":"Thiyagarajah MT, Herrmann N, Ruthirakuhan M, Li A, Lanct\u00f4t KL (2019) Novel pharmacologic strategies for treating behavioral disturbances in Alzheimer\u2019s disease. Curr Behav Neurosci Rep 6:72\u201387. https:\/\/doi.org\/10.1007\/s40473-019-00181-6","journal-title":"Curr Behav Neurosci Rep"},{"key":"8649_CR37","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40264-017-0543-0","volume":"40","author":"L Hirsch","year":"2017","unstructured":"Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T (2017) Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf 40:771\u2013781. https:\/\/doi.org\/10.1007\/s40264-017-0543-0","journal-title":"Drug Saf"},{"key":"8649_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11920-009-0006-0","volume":"11","author":"JO Brooks","year":"2009","unstructured":"Brooks JO, Chang H-S, Krasnykh O (2009) Metabolic risks in older adults receiving second-generation antipsychotic medication. Curr Psychiatry Rep 11:33\u201340. https:\/\/doi.org\/10.1007\/s11920-009-0006-0","journal-title":"Curr Psychiatry Rep"},{"key":"8649_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.phrs.2015.07.022","volume":"101","author":"LE Rojo","year":"2015","unstructured":"Rojo LE, Gaspar PA, Silva H, Risco L, Arena P, Cubillos-Robles K et al (2015) Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res 101:74\u201385. https:\/\/doi.org\/10.1016\/j.phrs.2015.07.022","journal-title":"Pharmacol Res"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08649-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08649-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08649-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T17:02:56Z","timestamp":1771347776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08649-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["8649"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08649-y","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent for publication is not applicable as this study involves publicly available data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No AI tools or technologies were used in the preparation of any part of this\u00a0manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of generative AI and AI-assisted technologies"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}